Free PSA is best marker for prostate cancer:
This article was originally published in Clinica
Executive Summary
Free PSA is a better diagnostic of malignancy in prostate cancer than the alternatives of age-specific PSA testing and PSA density calculation, according to a paper in this month's Urology. In the study, the Beckman Coulter Hybritech free-PSA test was found to be have the same sensitivity (95%) as a PSA density measurement, while also being less expensive because it does not need an ultrasound scan. The age-specific reference method was found to be less sensitive than free PSA, missing between 20% and 60% of cancers in men over 60 years old.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.